New Therapies for Acute Myeloid Leukemia

Dear Colleagues,

Acute myeloid leukemia (AML) is a high-mortality disease whose frequency and lethality increase with age. The standard treatment for eligible patients is based on the use of intensive chemotherapy with protocols that have not changed in decades. Usually, older and unfit patients cannot even receive these treatments. Demethylating agents and BCL2 inhibitors have been lately used in AML cases, but the results are still disappointing. Thus, new treatments are urgently needed for AML as it is the most common acute leukemia in adults, with the fifth worst survival rate among all cancers.

The discovery of gene mutations and rearrangements has allowed a new classification of AML with prognostic implications. Treatments targeting these molecular alterations have been recently developed. The increasing knowledge on the metabolic particularities of the leukemic cells and their epigenetic modifications have further opened new avenues for treating AML. Finally, immunotherapy with refined indications and new designs appears to be an important therapeutic tool. In this IJMS Special Issue, new therapies for AML will be explored in the hope of improving the prognosis of this condition.

Dr. Eduardo Anguita
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• acute myeloid leukemia
• BCL2 inhibitors
• leukemic cells
• new therapies for AML
• prognostic implications